Apyx Medical Corporation (APYX)
- Previous Close
1.2600 - Open
1.2800 - Bid 1.2600 x 100
- Ask 1.6700 x 200
- Day's Range
1.2800 - 1.4700 - 52 Week Range
1.2100 - 7.9700 - Volume
30,737 - Avg. Volume
157,279 - Market Cap (intraday)
45.384M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.63
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
apyxmedical.comRecent News: APYX
Performance Overview: APYX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APYX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APYX
Valuation Measures
Market Cap
44.17M
Enterprise Value
39.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.84
Price/Book (mrq)
1.65
Enterprise Value/Revenue
0.75
Enterprise Value/EBITDA
-2.15
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.75%
Return on Assets (ttm)
-18.80%
Return on Equity (ttm)
-58.25%
Revenue (ttm)
52.35M
Net Income Avi to Common (ttm)
-18.71M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
43.65M
Total Debt/Equity (mrq)
143.01%
Levered Free Cash Flow (ttm)
3.37M